Viral subversion of the immune system

Annual Review of Immunology

Volumn 18, Issue , 2000, Pages 861-926

  Tortorella, Domenico ^a   Gewurz, Benjamin E ^a   Furman, Margo H ^a   Schust, Danny J ^a   Ploegh, Hidde L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antigen presentation; Apoptosis; Complement; Cytokines; Viral evasion

Indexed keywords

CASPASE INHIBITOR; CD4 ANTIGEN; INTERFERON; INTERLEUKIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN BCL 2; TUMOR NECROSIS FACTOR RECEPTOR; VIRUS PROTEIN;

ANIMAL CELL; ANTIGEN PRESENTATION; APOPTOSIS; CYTOKINE PRODUCTION; GENE TARGETING; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE SYSTEM; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR INTERACTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VIRUS EXPRESSION;

ANIMALS; ANTIBODY FORMATION; ANTIGEN PRESENTATION; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DOWN-REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNE SYSTEM; KILLER CELLS, NATURAL;

EID: 0034080319     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.18.1.861     Document Type: Review

References (418)

1. Townsend A, H Bodmer. 1989. Antigen recognition by class I-restricted T lymphocytes. Annu. Rev. Immunol. 7:601-24
2. Brodsky FM, L Lem, A Solache, EM Bennett. 1999. Human pathogen subversion of antigen presentation. Immunol. Rev. 168:199-215
3. Doherty P. 1995. Immunity to viruses. Immunologist 3:231-33
4. Guidotti LG, FV Chisari. 1996. To kill or to cure: options in host defense against viral infection. Curr. Opin. Immunol. 8:478-83
5. Heemels MT, H Ploegh. 1995. Generation, translocation, and presentation of MHC class I-restricted peptides. Annu. Rev. Biochem. 64:463-91
6. Bjorkman PJ, MA Saper, B Samraoui, WS Bennett, JL Strominger, DC Wiley. 1987. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329:506-12
7. Rock KL. 1996. A new foreign policy: MHC class I molecules monitor the outside world. Immunol. Today 17:131-37
8. Williams DB, TH Watts. 1995. Molecular chaperones in antigen presentation. Curr. Opin. Immunol. 7:77-84
9. Hughes EA, P Cresswell. 1998. The thiol oxidoreductase ERp57 is a component of the MHC class I peptide-loading complex. Curr. Biol. 8:709-12
10. Lindquist JA, ON Jensen, M Mann, GJ Hammerling. 1998. ER-60, a chaperone with thiol-dependent reductase activity involved in MHC class I assembly. EMBO J. 17:2186-95
11. Ortmann B, J Copeman, PJ Lehner, B Sadasivan, JA Herberg, AG Grandea, SR Riddell, R Tampe, T Spies, J Trowsdale, P Cresswell. 1997. A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. Science 277:1306-9
12. Fruh K, A Gruhler, RM Krishna, GJ Schoenhals. 1999. A comparison of viral immune escape strategies targeting the MHC class I assembly pathway. Immunol. Rev. 168:157-66
13. Spriggs MK 1996. One step ahead of the game: viral immunomodulatory molecules. Annu. Rev. Immunol. 14:101-30
14. Khanna R, SR Burrows, PM Steigerwald-Mullen, SA Thomson, MG Kurilla, DJ Moss. 1995. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance. Virology 214:633-37
15. Levitskaya J, A Sharipo, A Leonchiks, A Ciechanover, MG Masucci. 1997. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. USA 94:12616-21
16. Murray, RJ, MG Kurilla, HM Griffin, JM Brooks, M Mackett, JR Arrand, M Rowe, SR Burrows, DJ Moss, E Kieff, AB Rickinson. 1990. Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses. Proc. Natl. Acad. Sci. USA 87:2906-10
17. Khanna R, SR Burrows, MG Kurilla, CA Jacob, IS Misko, TB Sculley, E Kieff, DJ Moss. 1992. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J. Exp. Med. 176:169-76
18. Sharipo A, M Imreh, A Leonchiks, S Imreh, MG Masucci. 1998. A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I kappaB alpha with the proteasome: a new mechanism for selective inhibition of proteolysis. Nat. Med. 4:939-44
19. Leonchiks A, E Liepinsh, M Barishev, A Sharipo, MG Masucci, G Otting. 1998. Random coil conformation of a Gly/Alarich insert in IkappaB alpha excludes structural stabilization as the mechanism for protection against proteasomal degradation. FEBS Lett. 440:365-69
20. Gilbert MJ, SR Riddell, CR Li, PD Greenberg. 1993. Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. J. Virol. 67:3461-69
21. Jahn G, BC Scholl, B Traupe, B Fleckenstein. 1987. The two major structural phosphoproteins (pp65 and pp150) of human cytomegalovirus and their antigenic properties. J. Gen. Virol. 68:1327-37
22. Ruger B, S Klages, B Walla, J Albrecht, B Fleckenstein, P Tomlinson, B Barrell. 1987. Primary structure and transcription of the genes coding for the two virion phosphoproteins pp65 and pp71 of human cytomegalovirus. J. Virol. 61:446-53
23. Gilbert MJ, SR Riddell, B Plachter, PD Greenberg. 1996. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature 383:720-22
24. Klenerman P, S Rowland-Jones, S McAdam, J Edwards, S Daenke, D Lalloo, B Koppe, W Rosenberg, D Boyd, A Edwards, et al. 1994. Cytotoxic T-cell activity antagonized by naturally occurring HTV-I Gag variants. Nature 369:403-7
25. Bertoletti A, A Sette, FV Chisari, A Penna, M Levrero, M De Carli, F Fiaccadori, C Ferrari. 1994. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 369:407-10
26. York IA, C Roop, DW Andrews, SR Riddell, FL Graham, DC Johnson. 1994. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8 + T lymphocytes. Cell 77:525-35
27. Hill A, P Jugovic, I York, G Russ, J Bennink, J Yewdell, H Ploegh, D Johnson. 1995. Herpes simplex virus turns off the TAP to evade host immunity. Nature 375:411-15
28. Fruh K, K Ahn, H Djaballah, P Sempe, PM van Endert, R Tampe, PA Peterson, Y Yang. 1995. A viral inhibitor of peptide transporters for antigen presentation. Nature 375:415-18
29. Galocha B, A Hill, BC Barnett, A Dolan, A Raimondi, RF Cook, J Brunner, DJ McGeoch, HL Ploegh. 1997. The active site of ICP47, a herpes simplex virus-encoded inhibitor of the major histocompatibility complex (MHC)-encoded peptide transporter associated with antigen processing (TAP), maps to the NH2-terminal 35 residues. J. Exp. Med. 185:1565-72
30. Ahn K, TH Meyer, S Uebel, P Sempe, H Djaballah, Y Yang, PA Peterson, K Fruh, R Tampe. 1996. Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47. EMBO J. 15:3247-55
31. Lacaille VG, MJ Androlewicz. 1998. Herpes simplex virus inhibitor ICP47 destabilizes the transporter associated with antigen processing (TAP) heterodimer. J. Biol. Chem. 273:17386-90
32. Jugovic P, AM Hill, R Tomazin, H Ploegh, DC Johnson. 1998. Inhibition of major histocompatibility complex class I antigen presentation in pig and primate cells by herpes simplex virus type 1 and 2 ICP47. J. Virol. 72:5076-84
33. Tomazin R, NE van School, K Goldsmith, P Jugovic, P Sempe, K Fruh, DC Johnson. 1998. Herpes simplex virus type 2ICP47 inhibits human TAP but not mouse TAP. J. Virol. 72:2560-63
34. Hengel H, T Flohr, GJ Hammerling UH Koszinowski, F Momburg. 1996. Human cytomegalovirus inhibits peptide translocation into the endoplasmic reticulum for MHC class I assembly. J. Gen. Virol. 77:2287-96
35. Hengel H, JO Koopmann, T Flohr, W Muranyi, E Goulmy, GJ Hammerling, UH Koszinowski, F Momburg. 1997. A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity 6:623-32
36. Ahn K, A Gruhler, B Galocha, TR Jones, EJ Wiertz, HL Ploegh, PA Peterson, Y Yang, K Fruh. 1997. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity 6:613-21
37. Lehner PJ, JT Karttunen, GW Wilkinson, P Cresswell. 1997. The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation. Proc. Natl. Acad. Sci. USA 94:6904-9
38. Cox JH, JR Bennink, JW Yewdell. 1991. Retention of adenovirus E19 glycoprotein in the endoplasmic reticulum is essential to its ability to block antigen presentation. J. Exp. Med. 174:1629-37
39. Burgert HG, S Kvist. 1987. The E3/19K protein of adenovirus type 2 binds to the domains of histocompatibility antigens required for CTL recognition. EMBO J. 6:2019-26
40. Jefferies WA, HG Burgert. 1990. E3/19K from adenovirus 2 is an immunosubversive protein that binds to a structural motif regulating the intracellular transport of major histocompatibility complex class I proteins. J.Exp. Med. 172:1653-64
41. Beier DC, JH Cox, DR Vining, P Cresswell, VH Engelhard. 1994. Association of human class I MHC alleles with the adenovirus E3/19K protein. J. Immunol. 152:3862-72
42. Paabo S, BM Bhat, WS Wold, PA Peterson. 1987. A short sequence in the COOH-terminus makes an adenovirus membrane glycoprotein a resident of the endoplasmic reticulum. Cell 50:311-17
43. Jackson MR, T Nilsson, PA Peterson. 1990. Identification of a consensus motif for retention of transmembrane proteins in the endoplasmic reticulum. EMBO J. 9:3153-62
44. Bennett EM, JR Bennink, JW Yewdell, FM Brodsky. 1999. Cutting edge: adenovirus E19 has two mechanisms for affecting class I MHC expression. J. lmmunol. 162:5049-52
45. Ahn K, A Angulo, P Ghazal, PA Peterson, Y Yang, K Fruh. 1996. Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proc. Natl. Acad. Sci USA 93:10990-95
46. Jones TR, EJ Wiertz, L Sun, KN Fish, JA Nelson, HL Ploegh. 1996. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class 1 heavy chains. Proc. Natl. Acad. Sci. USA 93:11327-33
47. Schust DJ, D Tortorella, J Seebach, C Phan, HL Ploegh. 1998. Trophoblast class I major histocompatibility complex (MHC) products are resistant to rapid degradation imposed by the human cytomegalovirus (HCMV) gene products US2 and US11. J. Exp. Med. 188:497-503
48. Wiertz EJ, D Tortorella, M Bogyo, J Yu, W Mothes, TR Jones, TA Rapoport, HL Ploegh. 1996. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature 384:432-38
49. Tortorella D, CM Story, JB Huppa, EJ Wiertz, TR Jones, I Bacik, JR Bennink, JW Yewdell, HL Ploegh. 1998. Dislocation of type I membrane proteins from the ER to the cytosol is sensitive to changes in redox potential. J. Cell Biol. 142:365-76
50. Suzuki T, A Seko, K Kitajima, Y Inoue, S Inoue. 1994. Purification and enzymatic properties of peptide:N-glycanase from C3H mouse-derived L-929 fibroblast cells: possible widespread occurrence of post-translational remodification of proteins by N-deglycosylation. J. Biol. Chem. 269:17611-18
51. Bankier AT, S Beck, R Bohni, CM Brown, R Cerny, MS Chee, CA Hutchison, T Kouzarides, JA Martignetti, E Preddie, et al. 1991. The DNA sequence of the human cytomegalovirus genome. DNA Seq. 2:1-12
52. Story CM, MH Furrnan, HL Ploegh. 1999. The cytosolic tail of class I MHC heavy chain is required for its dislocation by the human cytomegalovirus US2 and US11 gene products. Proc. Natl. Acad. Sci. USA 96:8516-21
53. Shamu CE, CM Story, TA Rapoport, HL Ploegh. 1999. The pathway of US11-dependent degradation of MHC class I heavy chains involves a ubiquitin-conjugated intermediate. J. Cell. Biol. 147:45-58
54. Plemper RK, DH Wolf. 1999. Retrograde protein translocation: eradication of secretory proteins in health and disease. Trends Biochem. Sci. 24:266-70
55. Ziegler H, R Thale, P Lucin, W Muranyi, T Flohr, H Hengel, H Farrell, W Rawlinson, UH Koszinowski. 1997. A mouse cytomegalovirus glycoprotein retains MHC class I complexes in the ERGIC/ cis-Golgi compartments. Immunity 6:57-66
56. Reusch U, W Muranyi, P Lucin, HG Burgert, H Hengel, UH Koszinowski. 1999. A cytomegalovirus glycoprotein reroutes MHC class I complexes to lysosomes for degradation. EMBO J. 18:1081-91
57. Kleijnen MF, JB Huppa, P Lucin, S Mukherjee, H Farrell, AE Campbell, UH Koszinowski, AB Hill, HL Ploegh. 1997. A mouse cytomegalovirus glycoprotein, gp34, forms a complex with folded class I MHC molecules in the ER which is not retained but is transported to the cell surface. EMBO J. 16:685-94
58. Piguet V, O Schwartz, S Le Gall, D Trono. 1999. The downregulation of CD4 and MHC-I by primate lentiviruses: a paradigm for the modulation of cell surface receptors. Immunol. Rev. 168:51-63
59. Le Gall S, L Erdtmann, S Benichou, C Berlioz-Torrent, L Liu, R Benarous, JM Heard, O Schwartz. 1998. Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity 8:483-95
60. Cohen GB, RT Gandhi, DM Davis, O Mandelboim, BK Chen, JL Strominger, D Baltimore. 1999. The selective down-regulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 10:661-71
61. Collins KL, BK Chen, SA Kalams, BD Walker, D Baltimore. 1998. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391:397-401
62. Greenberg ME, AJ Iafrate, J Skowronski. 1998. The SH3 domain-binding surface and an acidic motif in HIV-1 Nef regulate trafficking of class I MHC complexes. EMBO J. 17:2777-89
63. Mangasarian A, V Piguet, JK Wang, YL Chen, D Trono. 1999. Nef-induced CD4 and major histocompatibility complex class I (MHC-I) down-regulation are governed by distinct determinants: N-terminal alpha helix and proline repeat of Nef selectively regulate MHC-I trafficking. J. Virol. 73:1964-73
64. Riggs NL, HM Craig, MW Pandori, JC Guatelli. 1999. The dileucine-based sorting motif in HIV-1 Nef is not required for down-regulation of class I MHC. Virology 258:203-7
65. Marsh JW. 1999. The numerous effector functions of Nef. Arch. Biochem. Biophys. 365:192-98
66. Kerkau T, I Bacik, JR Bennink, JW Yewdell, T Hunig, A Schimpl, U Schubert. 1997. The human immunodeficiency virus type 1 (HIV-1) Vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules. J. Exp. Med. 185:1295-305
67. Wolf PR, HL Ploegh. 1995. How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway. Annu. Rev. Cell. Dev. Biol. 11:267-306
68. Pieters J. 1997. MHC class II restricted antigen presentation. Curr. Opin. lmmunol. 9:89-96
69. Jonjic S, W Mutter, F Weiland, MJ Reddehase, UH Koszinowski. 1989. Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes. J. Exp. Med. 169:1199-212
70. Chapman HA. 1998. Endosomal proteolysis and MHC class II function. Curr. Opin. Immunol. 10:93-102
71. Tomazin R, J Boname, NR Hegde, DM Lewinsohn, Y Altschuler, TR Jones, P Cresswell, JA Nelson, SR Riddell, DC Johnson. 1999. Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells. Nat. Med. 5:1039-43
72. Spriggs MK, RJ Armitage, MR Comeau, L Strockbine, T Farrah, B Macduff, D Ulrich, MR Alderson, J Mullberg, JI Cohen. 1996. The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation. J. Virol. 70:5557-63
73. Lewandowski GA, D Lo, FE Bloom. 1993. Interference with major histocompatibility complex class II-restricted antigen presentation in the brain by herpes simplex virus type 1 : a possible mechanism of evasion of the immune response. Proc. Natl. Acad. Sci. USA 90:2005-9
74. de Waal Malefyt R, J Haanen, H Spits, MG Roncarolo, A te Velde, C Figdor, K Johnson, R Kastelein, H Yssel, JE de Vries. 1991. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 174:915-24
75. Koppelman B, JJ Neefjes, JE de Vries, R de Waal Malefyt. 1997. Interleukin-10 down-regulates MHC class II alphabeta peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling. Immunity 7:861-71
76. Jackson T. 1998. Transport vesicles: coats of many colours. Curr. Biol. 8:R609-12
77. Tong X, W Boll, T Kirchhausen, PM Howley. 1998. Interaction of the bovine papillomavirus E6 protein with the clathrin adaptor complex AP-1. J. Virol. 72:476-82
78. Andresson T, J Sparkowski, DJ Goldstein, R Schlegel. 1995. Vacuolar H(+)-ATPase mutants transform cells and define a binding site for the papillomavirus E5 oncoprotein. J. Biol. Chem. 270:6830-37
79. Martin P, WC Vass, JT Schiller, DR Lowy, TJ Velu. 1989. The bovine papillomavirus E5 transforming protein can stimulate the transforming activity of EGF and CSF-1 receptors. Cell 59:21-32
80. Straight SW, PM Hinkle, RJ Jewers, DJ McCance. 1993. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the down-regulation of the epidermal growth factor receptor in keratinocytes. J. Virol. 67:4521-32
81. Waters CM, KA Overholser, A Sorkin, G Carpenter. 1992. Analysis of the influences of the E5 transforming protein on kinetic parameters of epidermal growth factor binding and metabolism. J. Cell Physiol. 152:253-63
82. Lu X, H Yu, SH Liu, FM Brodsky, BM Peterlin. 1998. Interactions between HIV 1 Nef and vacuolar ATPase facilitate the internalization of CD4. Immunity 8:647-56
83. Boss JM. 1997. Regulation of transcription of MHC class II genes. Curr. Opin. Immunol. 9:107-13
84. Rinaldo CR Jr. 1994. Modulation of major histocompatibility complex antigen expression by viral infection. Am. J. Pathol. 144:637-50
85. Miller DM, BM Rahill, JM Boss, MD Lairmore, JE Durbin, JW Waldman, DD Sedmak. 1998. Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway. J. Exp. Med. 187:675-83
86. Miller DM, Y Zhang, BM Rahill, WJ Waldman, DD Sedmak. 1999. Human cytomegalovirus inhibits IFN-alpha-stimulated antiviral and immunoregulatory responses by blocking multiple levels of IFN-alpha signal transduction. J. Immunol. 162:6107-13
87. Leonard GT, GC Sen. 1996. Effects of adenovirus E1A protein on interferon-signaling. Virology 224:25-33
88. Leonard GT, GC Sen. 1997. Restoration of Interferon responses of adenovirus E1A-expressing HT1080 cell lines by overexpression of p48 protein. J. Virol. 71:5095-101
89. Heise MT, HW Virgin. 1995. The T-cell-independent role of gamma Interferon and tumor necrosis factor alpha in macrophage activation during murine cytomegalovirus and herpes simplex virus infections. J. Virol. 69:904-9
90. Heise MT, M Connick, HW Virgin. 1998. Murine cytomegalovirus inhibits interferon gamma-induced antigen presentation to CD4 T cells by macrophages via regulation of expression of major histocompatibility complex class II-associated genes. J. Exp. Med. 187:1037-46
91. Oldridge J, M Marsh. 1998. Nef - an adaptor adaptor? Trends Cell. Biol. 8:302-5
92. McDougal JS, JK Nicholson, GD Cross, SP Cort, MS Kennedy, AC Mawle. 1986. Binding of the human retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4) molecule: conformation dependence, epitope mapping, antibody inhibition, and potential for idiotypic mimicry. J. Immunol. 137:2937-44
93. Maddon PJ, AG Dalgleish, JS McDougal, PR Clapham, RA Weiss, R Axel. 1986. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47:333-48
94. Klatzmann D, E Champagne, S Chamaret, J Gruest, D Guetard, T Hercend, JC Gluckman, L Montagnier. 1984. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 312:767-68
95. Dittmar MT, A McKnight, G Simmons, PR Clapham, RA Weiss, P Simmonds. 1997. HIV-1 tropism and co-receptoruse. Nature 385:495-96
96. Connor RI, KE Sheridan, D Ceradini, S Choe, NR Landau. 1997. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185:621-28
97. Lama J, A Mangasarian, D Trono. 1999. Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef-and Vpu-inhibitable manner. Curr. Biol. 9:622-31
98. Ross TM, AE Oran, BR Cullen. 1999. Inhibition of HIV-1 progeny virion release by cell-surface CD4 is relieved by expression of the viral Nef protein. Curr. Biol. 9:613-21
99. Aiken C, J Konner, NR Landau, ME Lenburg, D Trono. 1994. Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 76:853-64
100. Hua J, BR Cullen. 1997. Human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus Nef use distinct but overlapping target sites for downregulation of cell surface CD4. J. Virol. 71:6742-48
101. Grzesiek S, SJ Stahl, PT Wingfield, A Bax. 1996. The CD4 determinant for downregulation by HIV-1 Nef directly binds to Nef: mapping of the Nef binding surface by NMR. Biochemistry 35: 10256-61
102. Grzesiek S, A Bax, GM Clore, AM Gronenborn, JS Hu, J Kaufman, I Palmer, SJ Stahl, PT Wingfield. 1996. The solution structure of HIV-1 Nef reveals an unexpected fold and permits delineation of the binding surface for the SH3 domain of Hck tyrosine protein kinase. Nat. Struct. Biol. 3:340-45
103. Greenberg ME, S Bronson, M Lock, M Neumann, GN Pavlakis, J Skowronski. 1997. Co-localization of HIV-1 Nef with the AP-2 adaptor protein complex correlates with Nef-induced CD4 down-regulation. EMBO J. 16:6964-76
104. Piguet V, YL Chen, A Mangasarian, M Foti, JL Carpentier, D Trono. 1998. Mechanism of Nef-induced CD4 endocytosis: Nef connects CD4 with the mu chain of adaptor complexes. EMBO J. 17:2472-81
105. Iafrate AJ, S Bronson, J Skowronski. 1997. Separable functions of Nef disrupt two aspects of T cell receptor machinery: CD4 expression and CD3 signaling. EMBO J. 16:673-84
106. Bresnahan PA, W Yonemoto, S Ferrell, D Williams-Herman, R Geleziunas, WC Greene. 1998. A dileucine motif in HIV-1 Nef acts as an internalization signal for CD4 downregulation and binds the AP-1 clathrin adaptor. Curr. Biol. 8:1235-38
107. Greenberg M, L DeTulleo, I Rapoport, J Skowronski, T Kirchhausen. 1998. A dileucine motif in HIV-1 Nef is essential for sorting into clathrin-coated pits and for downregulation of CD4. Curr. Biol. 8:1239-42
108. Lock M, ME Greenberg, AJ Iafrate, T Swigut, J Muench, F Kirchhoff, N Shohdy, J Skowronski. 1999. Two elements target SIV Nef to the AP-2 clathrin adaptor complex, but only one is required for the induction of CD4 endocytosis. EMBO J. 18:2722-33
109. Craig HM, MW Pandori, JC Guatelli. 1998. Interaction of HIV-1 Nef with the cellular dileucine-based sorting pathway is required for CD4 down-regulation and optimal viral infectivity. Proc. Natl. Acad. Sci. USA 95:11229-34
110. Mangasarian A, M Foti, C Aiken, D Chin, JL Carpentier, D Trono. 1997. The HIV-1 Nef protein acts as a connector with sorting pathways in the Golgi and at the plasma membrane. Immunity 6:67-77
111. Benichou S, M Bomsel, M Bodeus, H Durand, M Doute, F Letourneur, J Camonis, R Benarous. 1994. Physical interaction of the HIV-1 Nef protein with beta-COP, a component of non-clathrin-coated vesicles essential for membrane traffic. J. Biol. Chem. 269:30073-76
112. Piguet V, F Gu, M Foti, N Demaurex, J Gruenberg, JL Carpentier, D Trono. 1999. Nef-induced CD4 degradation: a diacidic-based motif in Nef functions as a lysosomal targeting signal through the binding of beta-COP in endosomes. Cell 97:63-73
113. Barry M, SF Lee, L Boshkov, G McFadden. 1995. Myxoma virus induces extensive CD4 downregulation and dissociation of p56Ick in infected rabbit CD4+ T lymphocytes. J. Virol. 69: 5243-51
114. Secchiero P, D Gibellini, L Flamand, I Robuffo, M Marchisio, S Capitani, RC Gallo, G Zauli. 1997. Human herpesvirus 7 induces the down-regulation of CD4 antigen in lymphoid T cells without affecting p56Ick levels. J. Immunol. 159:3412-23
115. Strebel K, T Klimkait, MA Martin. 1988. A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science 241:1221-23
116. Matsuda Z, MJ Chou, M Matsuda, JH Huang, YM Chen, R Redfield, K Mayer, M Essex, TH Lee. 1988. Human immunodeficiency virus type 1 has an additional coding sequence in the central region of the genome. Proc. Natl. Acad. Sci. USA 85:6968-72
117. Cohen EA, EF Terwilliger, JG Sodroski, WA Haseltine. 1988. Identification of a protein encoded by the vpu gene of HIV-1. Nature 334:532-34
118. Maldarelli F, MY Chen, RL Willey, K Strebel. 1993. Human immunodeficiency virus type 1 Vpu protein is an oligomeric type I integral membrane protein. J. Virol. 67:5056-61
119. Wray V, T Federau, P Henklein, S Klabunde, O Kunert, D Schomburg, U Schubert. 1995. Solution structure of the hydrophilic region of HIV-1 encoded virus protein U (Vpu) by CD and 1H NMR spectroscopy. Int. J. Pept. Protein Res. 45:35-43
120. Schubert U, K Strebel. 1994. Differential activities of the human immunodeficiency virus type 1-encoded Vpu protein are regulated by phosphorylation and occur in different cellular compartments. J. Virol. 68:2260-71
121. Paul M, MA Jabbar. 1997. Phosphorylation of both phosphoacceptor sites in the HIV-1 Vpu cytoplasmic domain is essential for Vpu-mediated ER degradation of CD4. Virology 232:207-16
122. Tiganos E, XJ Yao, J Friborg, N Daniel, EA Cohen. 1997. Putative alpha-helical structures in the human immunodeficiency virus type 1 Vpu protein and CD4 are involved in binding and degradation of the CD4 molecule. J. Virol. 71:4452-60
123. Margottin F, S Benichou, H Durand, V Richard, LX Liu, E Gomas, R Benarous. 1996. Interaction between the cytoplasmic domains of HIV-1 Vpu and CD4: role of Vpu residues involved in CD4 interaction and in vitro CD4 degradation. Virology 223:381-86
124. Schubert U, LC Anton, I Bacik, JH Cox, S Bour, JR Bennink, Morlowski, K Strebel, JW Yewdell. 1998. CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J. Virol. 72:2280-88
125. van der Voorn L, HL Ploegh. 1992. The WD-40 repeat. FEBS Lett. 307:131-34
126. Margottin F, SP Bour, H Durand, L Selig, S Benichou, V Richard, D Thomas, K Strebel, R Benarous. 1998. A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol. Cell. 1:565-74
127. Bai C, P Sen, K Hofmann, L Ma, M Goebl, JW Harper, SJ Elledge. 1996. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 86:263-74
128. Hussell T, PJ Openshaw. 1998. Intracellular IFN-gamma expression in natural killer cells precedes lung CD8+ T cell recruitment during respiratory syncytial virus infection. J. Gen. Virol.79:2593-601
129. Bukowski JF, BA Woda, S Habu, K Okumura, RM Welsh. 1983. Natural killer cell depletion enhances virus synthesis and virus-induced hepatitis in vivo. J. lmmunol. 131:1531-38
130. Shellam GR, JE Allan, JM Papadimitriou, GJ Bancroft. 1981. Increased susceptibility to cytomegalovirus infection in beige mutant mice. Proc. Natl. Acad. Sci. USA 78:5104-8
131. Welsh RM, JO Brubaker, M Vargas-Cortes, CL O'Donnell. 1991. Natural killer (NK) cell response to virus infections in mice with severe combined immunodeficiency: the stimulation of NK cells and the NK cell-dependent control of virus infections occur independently of T and B cell function. J. Exp. Med. 173:1053-63
132. Welsh RM, CL O'Donnell, LD Shultz. 1994. Antiviral activity of NK 1.1 + natural killer cells in C57BL/6 SCID mice infected with murine cytomegalovirus. Nat. Immun. 13:239-45
133. Bukowski JF, BA Woda, RM Welsh. 1984. Pathogenesis of murine cytomegalovirus infection in natural killer cell-depleted mice. J. Virol. 52:119-28
134. Bukowski JF, JF Warner, G Dennert, RM Welsh. 1985. Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo. J. Exp. Med. 161:40-52
135. Scalzo AA, NA Fitzgerald, CR Wallace, AE Gibbons, YC Smart, RC Burton, GR Shellam. 1992. The effect of the Cmv-1 resistance gene, which is linked to the natural killer cell gene complex, is mediated by natural killer cells. J. Immunol. 149:581-89
136. Biron CA, KS Byron, JL Sullivan. 1989. Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. Med. 320:1731-35
137. Bruunsgaard H, C Pedersen, P Skinhoj, BK Pedersen. 1997. Clinical progression of HIV infection: role of NK cells. Scand. J. Immunol. 46:91-95
138. Ljunggren HG, K Karre. 1990. In search of the missing self: MHC molecule and NK cell recognition. Immunol. Today 11:237-44
139. Senkevich TG, JJ Bugert, JR Sister, EV Koonin, G Darai, B Moss. 1996. Genome sequence of a human tumorigenic poxvirus: prediction of specific host response-evasion genes. Science 273: 813-16
140. Farrell HE, NJ Davis-Poynter. 1998. From sabotage to camouflage: viral evasion of cytotoxic T lymphocyte and natural killer cell-mediated immunity. Semin. Cell. Dev. Biol. 9:369-78
141. Rawlinson WD, HE Farrell, BG Barrell. 1996. Analysis of the complete DNA sequence of murine cytomegalovirus. J. Virol. 70:8833-49
142. Beck S, BG Barrell. 1988. Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens. Nature 331:269-72
143. Farrell HE, H Vally, DM Lynch, P Fleming, GR Shellam, AA Scalzo, NJ Davis-Poynter. 1997. Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo. Nature 386:510-14
144. Tay CH, LY Yu, V Kumar, L Mason, JR Ortaldo, RM Welsh. 1999. The role of LY49 NK cell subsets in the regulation of murine cytomegalovirus infections. J. Immunol. 162:718-26
145. Kubota A, S Kubota, HE Farrell, N Davis-Poynter, F Takei. 1999. Inhibition of NK cells by murine CMV-encoded class I MHC homologue m144. Cell Immunol. 191:145-51
146. Cretney E, MA Degli-Esposti, EH Densley, HE Farrell, NJ Davis-Poynter, MJ Smyth. 1999. m144, a murine cytomegalovirus (MCMV)-encoded major histocompatibility complex class I homologue, confers tumor resistance to natural killer cell-mediated rejection. J. Exp. Med. 190:435-44
147. Chapman TL, PJ Bjorkman. 1998. Characterization of a murine cytomegalovirus class I major histocompatibility complex (MHC) homolog: comparison to MHC molecules and to the human cytomegalovirus MHC homolog. J. Virol. 72:460-66
148. Browne H, G Smith, S Beck, T Minson. 1990. A complex between the MHC class I homologue encoded by human cytomegalovirus and beta 2 microglobulin. Nature 347:770-72
149. Beersma MF, MJ Bijlmakers, HL Ploegh. 1993. Human cytomegalovirus down-regulates HLA class I expression by reducing the stability of class I H chains. J. Immunol. 151:4455-64
150. Fahnestock ML, JL Johnson, RM Feldman, JM Neveu, WS Lane, PJ Bjorkman. 1995. The MHC class I homolog encoded by human cytomegalovirus binds endogenous peptides. Immunity 3:583-90
151. Reyburn HT, O Mandelboim, M Vales-Gomez, DM Davis, L Pazmany, JL Strominger. 1997. The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells. Nature 386:514-17
152. Ho EL, JW Heusel, MG Brown, K Matsumoto, AA Scalzo, WM Yokoyama. 1998. Murine Nkg2d and Cd94 are clustered within the natural killer complex and are expressed independently in natural killer cells. Proc. Natl. Acad. Sci. USA 95:6320-25
153. Lazetic S, C Chang, JP Houchins, LL Lanier, JH Phillips. 1996. Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits. J. Immunol. 157:4741-45
154. Vance RE, DM Tanamachi, T Hanke, DH Raulet. 1997. Cloning of a mouse homolog of CD94 extends the family of C-type lectins on murine natural killer cells. Eur. J. Immunol. 27:3236-41
155. Vance RE, JR Kraft, JD Altman, PE Jensen, DH Raulet. 1998. Mouse CD94/ NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1(b). J. Exp. Med. 188:1841-48
156. Cosman D, N Fanger, L Borges, M Kubin, W Chin, L Peterson, ML Hsu. 1997. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 7:273-82
157. Vitale M, R Castriconi, S Parolini, D Pende, ML Hsu, L Moretta, D Cosman, A Moretta. 1999. The leukocyte Ig-like receptor (LIR)-1 for the cytomegalovirus UL18 protein displays a broad specificity for different HLA class I alleles: analysis of LIR-1 + NK cell clones. Int. Immunol. 11:29-35
158. Browne H, M Churcher, T Minson. 1992. Construction and characterization of a human cytomegalovirus mutant with the UL18 (class I homolog) gene deleted. J. Virol. 66:6784-87
159. Fletcher JM, HG Prentice, JE Grundy. 1998. Natural killer cell lysis of cytomegalovirus (CMV)-infected cells correlates with virally induced changes in cell surface lymphocyte function-associated antigen-3 (LFA-3) expression and not with the CMV-induced down-regulation of cell surface class I HLA. J. lmmunol. 161:2365-74
160. Tanaka Y, SS Tevethia. 1988. Differential effect of adenovirus 2 E3/19K glycoprotein on the expression of H-2Kb and H-2Db class I antigens and H-2Kb-and H-2Db-restricted SV40-specific CTL-mediated lysis. Virology 165:357-66
161. York IA, DC Johnson. 1993. Direct contact with herpes simplex virus-infected cells results in inhibition of lymphokine-activated killer cells because of cell-to-cell spread of virus. J. Infect. Dis. 168:1127-32
162. Posavad CM, JJ Newton, KL Rosenthal. 1993. Inhibition of human CTL-mediated lysis by fibroblasts infected with herpes simplex virus. J. lmmunol. 151:4865-73
163. Schust DJ, AB Hill, HL Ploegh. 1996. Herpes simplex virus blocks intracellular transport of HLA-G in placentally derived human cells. J. lmmunol. 157:3375-80
164. Shresta S, CT Pham, DA Thomas, TA Graubert, TJ Ley. 1998. How do cytotoxic lymphocytes kill their targets? Curr. Opin. lmmunol. 10:581-87
165. Cuff S, J Ruby. 1996. Evasion of apoptosis by DNA viruses, lmmunol. Cell. Biol. 74:527-37
166. Barry M, G McFadden. 1998. Apoptosis regulators from DNA viruses. Curr. Opin. lmmunol. 10:422-30
167. Tschopp J, M Thome, K Hofmann, E Meinl. 1998. The fight of viruses against apoptosis. Curr. Opin. Genet. Dev. 8:82-87
168. Teodoro JG, PE Branton. 1997. Regulation of apoptosis by viral gene products. J. Virol. 71:1739-46
169. Wold WS, K Doronin, K Toth, M Kuppuswamy, DL Lichtenstein, AE Tollefson. 1999. Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. Curr. Opin. lmmunol. 11:380-86
170. Meinl E, H Fickenscher, M Thome, J Tschopp, B Fleckenstein. 1998. Anti-apoptotic strategies of lymphotropic viruses. lmmunol. Today 19:474-79
171. Ashkenazi A, VM Dixit. 1998. Death receptors: signaling and modulation. Science 281:1305-8
172. Nagata S. 1997. Apoptosis by death factor. Cell 88:355-65
173. Schreiber M, L Sedger, G McFadden. 1997. Distinct domains of M-T2, the myxoma virus tumor necrosis factor (TNF) receptor homolog, mediate extra-cellular TNF binding and intracellular apoptosis inhibition. J. Virol. 71:2171-81
174. Smith CA, FQ Hu, TD Smith, CL Richards, P Smolak, RG Goodwin, DJ Pickup. 1996. Cowpox virus genome encodes a second soluble homologue of cellular TNF receptors, distinct from CrmB, that binds TNF but not LT alpha Virology 223:132-47
175. Loparev VN, JM Parsons, JC Knight, JF Panus, CA Ray, RM Buller, DJ Pickup, JJ Esposito. 1998. A third distinct tumor necrosis factor receptor of orthopoxviruses. Proc. Natl. Acad. Sci. USA 95:3786-91
176. Hu FQ, CA Smith, DJ Pickup. 1994. Cowpox virus contains two copies of an early gene encoding a soluble secreted form of the type II TNF receptor. Virology 204:343-56
177. Alcami A, A Khanna, NL Paul, GL Smith. 1999. Vaccinia virus strains Lister, USSR and Evans express soluble and cell-surface tumour necrosis factor receptors. J. Gen. Virol. 80:949-59
178. Benedict CA, KD Butrovich, NS Lurain, J Corbeil, I Rooney, P Schneider, J Tschopp, CF Ware. 1999. Cutting edge: a novel viral TNF receptor superfamily member in virulent strains of human cytomegalovirus. J. Immunol. 162:6967-70
179. Elsing A, HG Burgert. 1998. The adenovirus E3/10.4K-14.5K proteins down-modulate the apoptosis receptor Fas/ Apo-1 by inducing its internalization. Proc. Natl. Acad. Sci. USA 95:10072-77
180. Shisler J, C Yang, B Walter, CF Ware, LR Gooding. 1997. The adenovirus E3-10.4K/14.5K complex mediates loss of cell surface Fas (CD95) and resistance to Fas-induced apoptosis. J. Virol. 71:8299-306
181. Tollefson AE. 1998. Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature 392:726-30
182. Carlin CR, AE Tollefson, HA Brady, BL Hoffman, WS Wold. 1989. Epidermal growth factor receptor is down-regulated by a 10,400 MW protein encoded by the E3 region of adenovirus. Cell 57:135-44
183. Tollefson AE, AR Stewart, SP Yei, SK Saha, WS Wold. 1991. The 10,400-and 14,500-dalton proteins encoded by region E3 of adenovirus form a complex and function together to down-regulate the epidermal growth factor receptor. J. Virol. 65:3095-105
184. Dimitrov T, P Krajcsi, TW Hermiston, AE Tollefson, M Hannink, WS Wold. 1997. Adenovirus E3-10.4K/14.5K protein complex inhibits tumor necrosis factor-induced translocation of cytosolic phospholipase A2 to membranes. J, Virol. 71:2830-37
185. Krajcsi P, T Dimitrov, TW Hermiston, AE Tollefson, TS Ranheim, SB Vande Pol, AH Stephenson, WS Wold. 1996. The adenovirus E3-14.7K protein and the E3-10.4K/14.5K complex of proteins, which independently inhibit tumor necrosis factor (TNF)-induced apoptosis, also independently inhibit TNF-induced release of arachidonic acid. J. Virol. 70:4904-13
186. Thome TE, C Voelkel-Johnson, WM Casey, LW Parks, SM Laster. 1996. The activity of cytosolic phospholipase A2 is required for the lysis of adenovirus-infected cells by tumor necrosis factor. J. Virol. 70:8502-7
187. Tschopp J, M Irmler, M Thome. 1998. Inhibition of fas death signals by FLIPs. Curr. Opin. Immunol. 10:552-58
188. Thome M, P Schneider, K Hofmann, H Fickenscher, E Meinl, F Neipel, C Mattmann, K Burns, JL Bodmer, M Schroter, C Scaffidi, PH Krammer, ME Peter, J Tschopp. 1997. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386:517-21
189. Bertin J, RC Armstrong, S Ottilie, DA Martin, Y Wang, S Banks, GH Wang, TG Senkevich, ES Alnemri, B Moss, MJ Lenardo, KJ Tomaselli, JI Cohen. 1997. Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas-and TNFR1-induced apoptosis. Proc. Natl. Acad. Sci. USA 94:1172-76
190. Hu S, C Vincenz, M Buller, VM Dixit. 1997. A novel family of viral death effector domain-containing molecules that inhibit both CD-95-and tumor necrosis factor receptor-1-induced apoptosis. J. Biol. Chem. 272:9621-24
191. Thornberry NA, Y Lazebnik. 1998. Caspases: enemies within. Science 281: 1312-16
192. Dbaibo GS, YA Hannun. 1998. Cytokine response modifier A (CrmA): a strategically deployed viral weapon. Clin. Immu-nol. Immunopathol. 86:134-40
193. Macen J, A Takahashi, KB Moon, R Nathaniel, PC Turner, RW Moyer. 1998. Activation of caspases in pig kidney cells infected with wild-type and CrmA/SPI-2 mutants of cowpox and rabbitpox viruses. J. Virol. 72:3524-33
194. Dobbelstein M, T Shenk. 1996. Protection against apoptosis by the vaccinia virus SPI-2 (B13R) gene product. J. Virol. 70:6479-85
195. Kettle S, A Alcami, A Khanna, R Ehret, C Jassoy, GL Smith. 1997. Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1beta-converting enzyme and protects virus-infected cells from TNF-and Fas-mediated apoptosis, but does not prevent IL-1beta-induced fever. J. Gen. Virol. 78:677-85
196. Virgin HW, P Latreille, P Wamsley, K Hallsworth, KE Week, AJ Dal Canto, SH Speck. 1997. Complete sequence and genomic analysis of murine gammaherpesvirus 68. J. Virol. 71:5894-904
197. Miller LK. 1997. Baculovirus interaction with host apoptotic pathways. J. Cell. Physiol. 173:178-82
198. Deveraux QL, JC Reed. 1999. IAP family proteins - suppressors of apoptosis. Genes Dev. 13:239-52
199. Rothe M, MG Pan, WJ Henzel, TM Ayres, DV Goeddel. 1995. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 83:1243-52
200. Deveraux QL, R Takahashi, GS Salvesen, JC Reed. 1997. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388:300-4
201. Neilan JG, Z Lu, GF Kutish, L Zsak, TG Burrage, MV Borca, C Carrillo, DL Rock. 1997. A BIR motif containing gene of African swine fever virus, 4CL, is nonessential for growth in vitro and viral virulence. Virology 230:252-64
202. Chen P, J Tian, I Kovesdi, JT Bruder. 1998. Interaction of the adenovirus 14.7-kDa protein with FLICE inhibits Fas ligand-induced apoptosis. J. Biol. Chem. 273:5815-20
203. Li Y, J Kang, MS Horwitz. 1998. Interaction of an adenovirus E3 14.7-kilodalton protein with a novel tumor necrosis factor alpha-inducible cellular protein containing leucine zipper domains. Mol. Cell. Biol. 18:1601-10
204. Li Y, J Kang, MS Horwitz. 1997. Interaction of an adenovirus 14.7-kilodalton protein inhibitor of tumor necrosis factor alpha cytolysis with a new member of the GTPase superfamily of signal transducers. J. Virol. 71:1576-82
205. Li Y, J Kang, J Friedman, L Tarassishin, J Ye, A Kovalenko, D Wallach, MS Horwitz. 1999. Identification of a cell protein (FIP-3) as a modulator of NF-kappaB activity and as a target of an adenovirus inhibitor of tumor necrosis factor alpha-induced apoptosis. Proc. Natl. Acad. Sci. USA 96:1042-47
206. Adams JM, S Cory. 1998. The Bcl-2 protein family: arbiters of cell survival. Science 281:1322-26
207. Chao DT, SJ Korsmeyer. 1998. BCL-2 family: regulators of cell death. Annu. Rev. Immunol. 16:395-419
208. Cheng EH, J Nicholas, DS Bellows, GS Hayward, HG Guo, MS Reitz, JM Hardwick. 1997. A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. Proc. Natl. Acad. Sci. USA 94:690-94
209. Brun A, C Rivas, M Esteban, JM Escribano, C Alonso. 1996. African swine fever virus gene A179L, a viral homologue of bcl-2, protects cells from programmed cell death. Virology 225:227-30
210. Ensser A, R Pflanz, B Fleckenstein. 1997. Primary structure of the alcelaphine herpesvirus 1 genome. J. Virol. 71:6517-25
211. Henderson S, D Huen, M Rowe, C Dawson, G Johnson, A Rickinson. 1993. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc. Natl. Acad. Sci. USA 90:8479-83
212. Nava VE, EH Cheng, M Veliuona, S Zou, RJ Clem, ML Mayer, JM Hardwick. 1997. Herpesvirus saimiri encodes a functional homolog of the human bcl-2 oncogene. J. Virol 71:4118-22
213. Sarid R, T Sato, RA Bohenzky, JJ Russo, Y Chang. 1997. Kaposi's sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nat. Med. 3:293-98
214. Telford EA, MS Watson, HC Aird, J Perry, AJ Davison. 1995. The DNA sequence of equine herpesvirus 2. J. Mol. Biol. 249:520-28
215. Tarodi B, T Subramanian, G Chinnadurai. 1994. Epstein-Barr virus BHRF1 protein protects against cell death induced by DNA-damaging agents and heterologous viral infection. Virology 201:404-7
216. Marshall WL, C Yim, E Gustafson, T Graf, DR Sage, K Hanify, L Williams, J Fingeroth, RW Finberg. 1999. Epstein-Barr virus encodes a novel homolog of the bcl-2 oncogene that inhibits apoptosis and associates with Bax and Bak. J. Virol. 73:5181-85
217. Henderson S, M Rowe, C Gregory, D Croom-Carter, F Wang, R Longnecker, E Kieff, A Rickinson. 1991. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65:1107-15
218. Kieff E. 1996. Epstein-Barr virus and its replication. In Virology, ed. BC Fields, DM Knipe, PM Howley, Vol. 2, pp. 2343-96. New York: Lippincott-Raven. 3rd ed.
219. Farrell PJ. 1998. Signal transduction from the Epstein-Barr virus LMP-1 transforming protein. Trends Microbiol 6:175-78
220. Khanim F, C Dawson, CA Meseda, J Dawson, M Mackett, LS Young. 1997. BHRF1, a viral homologue of the Bcl-2 oncogene, is conserved at both the sequence and functional level in different Epstein-Barr virus isolates. J. Gen. Virol. 78:2987-99
221. Lee MA, JL Yates. 1992. BHRF1 of Epstein-Barr virus, which is homologous to human proto-oncogene bcl2, is not essential for transformation of B cells or for virus replication in vitro. J. Virol. 66:1899-906
222. Marchini A, B Tomkinson, JI Cohen, E Kieff. 1991. BHRF1, the Epstein-Barr virus gene with homology to Bc12, is dispensable for B-lymphocyte transformation and virus replication. J. Virol. 65:5991-6000
223. Huang DC, S Cory, A Strasser. 1997. Bcl-2, Bcl-XL and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death. Oncogene 14:405-14
224. Chen G, PE Branton, E Yang, SJ Korsmeyer, GC Shore. 1996. Adenovirus E1B 19-kDa death suppressor protein interacts with Bax but not with Bad. J. Biol. Chem. 271:24221-25
225. Kasof GM, L Goyal, E White. 1999. Btf, a novel death-promoting transcriptional repressor that interacts with Bcl-2-related proteins. Mol. Cell. Biol. 19:4390-404
226. Van Parijs L, A Biuckians, AK Abbas. 1998. Functional roles of Fas and Bcl-2-regulated apoptosis of T lymphocytes. J. Immunol. 160:2065-71
227. Shisler JL, TG Senkevich, MJ Berry, B Moss. 1998. Ultraviolet-induced cell death blocked by a selenoprotein from a human dermatotropic poxvirus. Science 279:102-5
228. Scheffner M, JM Huibregtse, RD Vierstra, PM Howley. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505
229. Leopardi R, C Van Sant, B Roizman. 1997. The herpes simplex virus 1 protein kinase US3 is required for protection from apoptosis induced by the virus. Proc. Natl. Acad. Sci. USA 94:7891-96
230. Zhu H, Y Shen, T Shenk. 1995. Human cytomegalovirus IE1 and IE2 proteins block apoptosis. J. Virol. 69:7960-70
231. Barry M, S Hnatiuk, K Mossman, SF Lee, L Boshkov, G McFadden. 1997. The myxoma virus M-T4 gene encodes a novel RDEL-containing protein that is retained within the endoplasmic reticulum and is important for the productive infection of lymphocytes. Virology 239: 360-77
232. Paul WE, ed. 1999. Fundamental Immunology. New York: Lippincott-Raven, 3rd ed.
233. Juang Y, W Lowther, M Kellum, WC Au, R Lin, J Hiscott, PM Pitha. 1998. Primary activation of interferon A and Interferon B gene transcription by interferon regulatory factor 3. Proc. Natl. Acad. Sci. USA 95:9837-42
234. Lin R, C Heylbroeck, PM Pitha, J Hiscott. 1998. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol. Cell. Biol. 18:2986-96
235. Mahr JA, LR Gooding. 1999. Immune evasion by adenoviruses. Immunol. Rev. 168:121-30
236. Hiscott J, P Pitha, P Genin, H Nguyen, C Heylbroeck, Y Mamane, M Algarte, R Lin. 1999. Triggering the interferon response: the role of IRF-3 transcription factor. J. Interferon Cytokine Res. 19:1-13
237. Hirsch AJ, T Shenk. 1999. Human cytomegalovirus inhibits transcription of the CC chemokine MCP-1 gene. J. Virol. 73:404-10
238. Petit F, S Bertagnoli, J Gelfi, F Fassy, C Boucraut-Baralon, A Milon. 1996. Characterization of a myxoma virus-encoded serpin-like protein with activity against interleukin-1 beta-converting enzyme. J. Virol. 70:5860-66
239. Messud-Petit F, J Gelfi, M Delverdier, MF Amardeilh, R Py, G Sutler, S Bertagnoli. 1998. Serp2, an inhibitor of the interleukin-1beta-converting enzyme, is critical in the pathobiology of myxoma virus. J. Virol. 72:7830-39
240. Nash P, J Barrett, JX Cao, S Hota-Mitchell, AS Lalani, H Everett, XM Xu, J Robichaud, S Hnatiuk, C Ainslie, BT Seet, G McFadden. 1999. Immunomodulation by viruses: the myxoma virus story. Immunol. Rev. 168:103-20
241. Muller G, J Saloga, T Germann, G Schuler, J Knop, AH Enk. 1995. IL-12 as mediator and adjuvant for the induction of contact sensitivity in vivo. J. Immunol. 155:4661-68
242. Karp CL 1999. Measles: immunosuppression, interleukin-12, and complement receptors, lmmunol. Rev. 168:91-101
243. Novick D, H Engelmann, D Wallach, M Rubinstein. 1989. Soluble cytokine receptors are present in normal human urine. J. Exp. Med. 170:1409-14
244. McFadden G, A Lalani, H Everett, P Nash, X Xu. 1998. Virus-encoded receptors for cytokines and chemokines. Semin. Cell. Dev. Biol. 9:359-68
245. Cha TA, E Tom, GW Kemble, GM Duke, ES Mocarski, RR Spaete. 1996. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J. Virol. 70:78-83
246. Symons JA, A Alcami, GL Smith. 1995. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81:551-60
247. Alcami A, GL Smith. 1995. Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J. Virol. 69:4633-39
248. Mossman K, C Upton, RM Buller, G McFadden. 1995. Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins. Virology 208:762-69
249. Smith GL 1996. Virus proteins that bind cytokines, chemokines or interferons. Curr. Opin. lmmunol. 8:467-71
250. Mossman K, C Upton, G McFadden. 1995. The myxoma virus-soluble interferon-gamma receptor homolog, M-T7, inhibits interferon-gamma in a species-specific manner. J. Biol. Chem. 270: 3031-38
251. Lalani AS, K Graham, K Mossman, K Rajarathnam, I Clark-Lewis, D Kelvin, G McFadden. 1997. The purified myxoma virus gamma Interferon receptor homolog M-T7 interacts with the heparinbinding domains of chemokines. J. Virol. 71:4356-63
252. Baggiolini M. 1998. Chemokines and leukocyte traffic. Nature 392:565-68
253. Schall TJ, KB Bacon. 1994. Chemokines, leukocyte trafficking, and inflammation. Curr. Opin. Immunol. 6:865-73
254. Smith CA, TD Smith, PJ Smolak, D Friend, H Hagen, M Gerhart, L Park, DJ Pickup, D Torrance, K Mohler, K Schooley, RG Goodwin. 1997. Poxvirus genomes encode a secreted, soluble protein that preferentially inhibits beta chemokine activity yet lacks sequence homology to known chemokine receptors. Virology 236:316-27
255. Alcami A, JA Symons, PD Collins, TJ Williams, GL Smith. 1998. Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J. Immunol. 160:624-33
256. Essani K, S Chalasani, R Eversole, L Beuving, L Birmingham. 1994. Multiple anti-cytokine activities secreted from tanapox virus-infected cells. Microb. Pathog. 17:347-53
257. Strockbine LD, JI Cohen, T Farrah, SD Lyman, F Wagener, RF DuBose, RJ Armitage, MK Spriggs. 1998. The Epstein-Barr virus BARF1 gene encodes a novel, soluble colony-stimulating factor-1 receptor. J. Virol. 72:4015-21
258. Spriggs MK. 1999. Virus-encoded modulators of cytokines and growth factors. Cytokine Growth Factor Rev. 10:1-4
259. Billstrom MA, GL Johnson, NJ Avdi, GS Worthen. 1998. lntracellular signaling by the chemokine receptor US28 during human cytomegalovirus infection. J. Virol. 72:5535-44
260. Bodaghi B, TR Jones, D Zipeto, C Vita, L Sun, L Laurent, F Arenzana-Seisdedos, JL Virelizier, S Michelson. 1998. Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: withdrawal of chemokines from the environment of cytomegalovirus-infected cells. J. Exp. Med. 188:855-66
261. Pleskoff O, C Treboute, A Brelot, N Heveker, M Seman, M Alizon. 1997. Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry. Science 276:1874-78
262. Nicholas J, KR Cameron, RW Honess. 1992. Herpesvirus saimiri encodes homologues of G protein-coupled receptors and cyclins. Nature 355:362-65
263. Kledal TN, MM Rosenkilde, F Coulin, G Simmons, AH Johnsen, S Alouani, CA Power, HR Luttichau, J Gerstoft, PR Clapham, I Clark-Lewis, TNC Wells, TW Schwartz. 1997. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science 277:1656-59
264. Cesarman E, RG Nador, F Bai, RA Bohenzky, JJ Russo, PS Moore, Y Chang, DM Knowles. 1996. Kaposi's sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi's sarcoma and malignant lymphoma. J. Virol. 70:8218-23
265. Bais C, B Santomasso, O Coso, L Arvanitakis, EG Raaka, JS Gutkind, AS Asch, E Cesarman, MC Gershengorn, EA Mesri, MC Gerhengorn. 1998. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391:86-89
266. Arvanitakis L, E Geras-Raaka, A Varma, MC Gershengorn, E Cesarman. 1997. Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 385:347-50
267. Geras-Raaka E, A Varma, H Ho, I Clark-Lewis, MC Gershengorn. 1998. Human interferon-gamma-inducible protein 10 (IP-10) inhibits constitutive signaling of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. J. Exp. Med. 188:405-8
268. Geras-Raaka E, A Varma, I Clark-Lewis, MC Gershengorn. 1998. Kaposi's sarcoma-associated herpesvirus (KSHV) chemokine vMIP-II and human SDF-1alpha inhibit signaling by KSHV G protein-coupled receptor. Biochem. Biophys. Res. Commun. 253:725-27
269. Beisser PS, C Vink, JG Van Dam, G Grauls, SJ Vanherle, CA Bruggeman. 1998. The R33 G protein-coupled receptor gene of rat cytomegalovirus plays an essential role in the pathogenesis of viral infection. J. Virol. 72:2352-63
270. Davis-Poynter NJ, DM Lynch, H Vally, GR Shellam, WD Rawlinson, BG Barrell, HE Farrell. 1997. Identification and characterization of a G protein-coupled receptor homolog encoded by murine cytomegalovirus. J. Virol. 71:1521-29
271. Yasukawa M, A Hasegawa, I Sakai, H Ohminami, J Arai, S Kaneko, Y Yakushijin, K Maeyama, H Nakashima, R Arakaki, S Fujita. 1999. Down-regulation of CXCR4 by human herpesvirus 6 (HHV-6) and HHV-7. J. Immunol. 162:5417-22
272. Secchiero P, D Zella, O Barabitskaja, MS Reitz, S Capitani, RC Gallo, G Zauli. 1998. Progressive and persistent down-regulation of surface CXCR4 in CD4( + ) T cells infected with human herpesvirus 7. Blood 92:4521-28
273. Darnon I, PM Murphy, B Moss. 1998. Broad spectrum chemokine antagonistic activity of a human poxvirus chemokine homolog. Proc. Natl. Acad. Sci. USA 95:6403-7
274. Krathwohl MD, R Hromas, DR Brown, HE Broxmeyer, KH Fife. 1997. Functional characterization of the C-C chemokine-like molecules encoded by molluscum contagiosum virus types 1 and 2. Proc. Natl. Acad. Sci. USA 94:9875-80
275. Baggiolini M, B Dewald, B Moser. 1997. Human chemokines: an update. Annu. Rev. Immunol. 15:675-705
276. Zou P, Y Isegawa, K Nakano, M Haque, Y Horiguchi, K Yamanishi. 1999. Human herpesvirus 6 open reading frame U83 encodes a functional chemokine. J. Virol. 73:5926-33
277. Fleming P, N Davis-Poynter, M DegliEsposti, E Densley, J Papadimitriou, G Shellam, H Farrell. 1999. The murine cytomegalovirus chemokine homolog, m131/129, is a determinant of viral pathogenicity. J. Virol. 73:6800-9
278. MacDonald MR, MW Burney, SB Resnick, HI Virgin. 1999. Spliced mRNA encoding the murine cytomegalovirus chemokine homolog predicts a beta chemokine of novel structure. J. Virol. 73:3682-91
279. Saederup N, Y Lin, DJ Dairaghi, TJ Schall, ES Mocarski. 1999. Cytomegalovirus-encoded beta chemokine promotes monocyte-associated viremia in the host. Proc. Natl. Acad. Sci. USA 96:10881-86
280. Neipel F, JC Albrecht, B Fleckenstein. 1997. Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity? J. Virol. 71:4187-92
281. Aoki Y, ES Jaffe, Y Chang, K Jones, J Teruya-Feldstein, PS Moore, G Tosato. 1999. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 93:4034-43
282. Nicholas J, VR Ruvolo, WH Burns, G Sandford, X Wan, D Ciufo, SB Hendrickson, HG Guo, GS Hayward, MS Reitz. 1997. Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nat. Med. 3:287-92
283. Rettig MB, HJ Ma, RA Vescio, M Pold, G Schiller, D Belson, A Savage, C Nishikubo, C Wu, J Fraser, JW Said, JR Berenson. 1997. Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 276:1851-54
284. Sallusto F, CR Mackay, A Lanzavecchia. 1997. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 277:2005-7
285. Bonecchi R, G Bianchi, PP Bordignon, D D'Ambrosio, R Lang, A Borsatti, S Sozzani, P Allavena, PA Gray, A Mantovani, F Sinigaglia. 1998. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J. Exp. Med. 187:129-34
286. Dairaghi DJ, RA Fan, BE McMaster, MR Hanley, TJ Schall. 1999. HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines. J. Biol. Chem. 274:21569-74
287. Endres MJ, CG Garlisi, H Xiao, L Shan, JA Hedrick. 1999. The Kaposi's sarcoma-related herpesvirus (KSHV)-encoded chemokine vMIP-I is a specific agonist for the CC chemokine receptor (CCR)8. J. Exp. Med. 189:1993-98
288. Sozzani S, W Luini, G Bianchi, P Allav ena, TN Wells, M Napolitano, G Bemardini, A Vecchi, D D'Ambrosio, D Mazzeo, F Sinigaglia, A Santoni, E Maggi, S Romagnani, A Mantovani. 1998. The viral chemokine macrophage inflammatory protein-II is a selective Th2 chemoattractant. Blood 92:4036-39
289. Moore PS, C Boshoff, RA Weiss, Y Chang. 1996. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 274:1739-44
290. D'Ambrosio D, A Iellem, R Bonecchi, D Mazzeo, S Sozzani, A Mantovani, F Sinigaglia. 1998. Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J. Immunol. 161:5111-15
291. Zingoni A, H Soto, JA Hedrick, A Stoppacciaro, CT Storlazzi, F Sinigaglia, D D'Ambrosio, A O'Garra, D Robinson, M Rocchi, A Santoni, A Zlotnik, M Napolitano. 1998. The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J. Immunol 161:547-51
292. Cayley PJ, JA Davies, KG McCullagh, IM Kerr. 1984. Activation of the ppp(A2'p)nA system in interferon-treated, herpes simplex virus-infected cells and evidence for novel inhibitors of the ppp(A2'p)nA-dependent RNase. Eur. J. Biochem. 143:165-74
293. Novick D, SH Kim, G Fantuzzi, LL Reznikov, CA Dinarello, M Rubinstein. 1999. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 10:127-36
294. Takeda K, H Tsutsui, T Yoshimoto, O Adachi, N Yoshida, T Kishimoto, H Okamura, K Nakanishi, S Akira. 1998. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 8:383-90
295. Puren AJ, G Fantuzzi, Y Gu, MS Su, CA Dinarello. 1998. Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J. Clin. Invest. 101:711-21
296. Liu Y, R de Waal Malefyt, F Briere, C Parham, JM Bridon, J Banchereau, KW Moore, J Xu. 1997. The EBV IL-10 homologue is a selective agonist with impaired binding to the IL-10 receptor. J. Immunol. 158:604-13
297. Kotenko SV, CD Krause, LS Izotova, BP Pollack, W Wu, S Pestka. 1997. Identification and functional characterization of a second chain of the interleukin-10 receptor complex. EMBO J. 16:5894-903
298. Helminen M, N Lahdenpohja, M Hurme. 1999. Polymorphism of the interleukin-10 gene is associated with susceptibility to Epstein-Barr virus infection. J. Infect. Dis. 180:496-99
299. Li M, H Lee, J Guo, F Neipel, B Fleckenstein, K Ozato, JU Jung. 1998. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor. J. Virol. 72:5433-40
300. He B, M Gross, B Roizman. 1997. The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc. Natl. Acad. Sci. USA 94:843-48
301. Taylor DR, ST Shi, PR Romano, GN Barber, MM Lai. 1999. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285:107-10
302. Davies MV, HW Chang, BL Jacobs, RJ Kaufman. 1993. The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms. J. Virol. 67:1688-92
303. Sharp TV, DA Raine, DR Gewert, B Joshi, R Jagus, MJ Clemens. 1999. Activation of the interferon-inducible (2'-5') oligoadenylate synthetase by the Epstein-Barr virus RNA, EBER-1. Virology 257:303-13
304. Ma Y, MB Mathews. 1996. Structure, function, and evolution of adenovirus-associated RNA: a phylogenetic approach. J. Virol. 70:5083-99
305. Clemens MJ 1993. The small RNAs of Epstein-Barr virus. Mol. Biol. Rep. 17:81-92
306. Dempsey PW, ME Allison, S Akkaraju, CC Goodnow, DT Fearon. 1996. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271:348-50
307. Fearon DT 1998. The complement system and adaptive immunity. Semin. Immunol. 10:355-61
308. Carroll MC 1998. The role of complement and complement receptors in induction and regulation of immunity. Annu. Rev. Immunol. 16:545-68
309. Anderson DR, CM Carthy, JE Wilson, D Yang, DV Devine, BM McManus. 1997. Complement component 3 interactions with coxsackievirus B3 capsid proteins: innate immunity and the rapid formation of splenic antiviral germinal centers. J. Virol. 71:8841-45
310. Reitter JN, RE Means, RC Desrosiers. 1998. A role for carbohydrates in immune evasion in AIDS. Nat. Med. 4:679-84
311. Lubinski J, T Nagashunmugam, HM Friedman. 1998. Viral interference with antibody and complement. Semin. Cell. Dev. Biol. 9:329-37
312. Dubin G, E Socolof, I Frank, HM Friedman. 1991. Herpes simplex virus type 1 Fc receptor protects infected cells from antibody-dependent cellular cytotoxicity. J. Virol. 65:7046-50
313. Chapman TL, I You, IM Joseph, PJ Bjorkman, SL Morrison, M Raghavan. 1999. Characterization of the interaction between the herpes simplex virus type I Fc receptor and immunoglobulin G. J. Biol. Chem. 274:6911-19
314. Deisenhofer J. 1981. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9-and 2.8-A resolution. Biochemistry 20:2361-70
315. Raghavan M, MY Chen, LN Gastinel, PJ Bjorkman. 1994. Investigation of the interaction between the class I MHC-related Fc receptor and its immunoglobulin G ligand. Immunity 1:303-15
316. Stone GC, U Sjobring, L Bjorck, J Sjoquist, CV Barber, FA Nardella. 1989. The Fc binding site for streptococcal protein G is in the C gamma 2-C gamma 3 interface region of IgG and is related to the sites that bind staphylococcal protein A and human rheumatoid factors. J. Immunol. 143:565-70
317. Favoreel HW, HJ Nauwynck, P Van Oostveldt, TC Mettenleiter, MB Pensaert. 1997. Antibody-induced and cytoskeleton-mediated redistribution and shedding of viral glycoproteins, expressed on pseudorabies virus-infected cells. J. Virol. 71:8254-61
318. Brown ZA, S Selke, J Zeh, J Kopelman, A Maslow, RL Ashley, DH Watts, S Berry, M Herd, L Corey. 1997. The acquisition of herpes simplex virus during pregnancy. N. Engl. J. Med. 337:509-15
319. Calderon J, EE Avila. 1986. Antibody-induced caps in Entamoeba histolytica: isolation and electrophoretic analysis. J. Infect. Dis. 153:927-32
320. Favoreel HW, HJ Nauwynck, HM Halewyck, P Van Oostveldt, TC Mettenleiter, MB Pensaert. 1999. Antibody-induced endocytosis of viral glycoproteins and major histocompatibility complex class I on pseudorabies virus-infected monocytes. J. Gen. Virol. 80:1283-91
321. Nagashunmugam T, J Lubinski, L Wang, LT Goldstein, BS Weeks, P Sundaresan, EH Kang, G Dubin, HM Friedman. 1998. In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor. J. Virol. 72:5351-59
322. Frank I, HM Friedman. 1989. A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G. J. Virol. 63:4479-88
323. Van Vliet KE, LA De Graaf-Miltenburg, J Verhoef, JA Van Strijp. 1992. Direct evidence for antibody bipolar bridging on herpes simplex virus-infected cells. Immunology 77:109-15
324. Burton GF, A Masuda, SL Heath, BA Smith, JG Tew, AK Szakal. 1997. Follicular dendritic cells (FDC) in retroviral infection: host/pathogen perspectives. Immunol. Rev. 156:185-97
325. Heath SL, JG Tew, JG Tew, AK Szakal, GF Burton. 1995. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 377:740-44
326. Embretson J, M Zupancic, JL Ribas, A Burke, P Racz, K Tenner-Racz, AT Haase. 1993. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362:359-62
327. Pantaleo G, C Graziosi, JF Dernarest, L Butini, M Montroni, CH Fox, JM Orenstein, DP Kotler, AS Fauci. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362:355-58
328. Ravetch JV. 1994. Fc receptors: rubor redux. Cell 78:553-60
329. Daeron M. 1997. Fc receptor biology. Annu. Rev. lmmunol. 15:203-34
330. D'Ambrosio D, KL Hippen, SA Minskoff, I Mellman, G Pani, KA Siminovitch, JC Cambier. 1995. Recruitment and activation of PTP1C in negative regulation of antigen receptor signaling by Fc gamma RIIB1. Science 268:293-97
331. Wagle NM, AE Faassen, JH Kim, SK Pierce. 1999. Regulation of B cell receptor-mediated MHC class II antigen processing by FcgammaRIIB1. J. lmmunol. 162:2732-40
332. Ravanel K, C Castelle, T Defrance, TF Wild, D Charron, V Lotteau, C Rabourdin-Combe. 1997. Measles virus nucleocapsid protein binds to FcgammaRII and inhibits human B cell antibody production. J. Exp. Med. 186:269-78
333. Kotwal GJ, SN Isaacs, R McKenzie, MM Frank, B Moss. 1990. Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science 250:827-30
334. McKenzie R, GJ Kotwal, B Moss, CH Hammer, MM Frank. 1992. Regulation of complement activity by vaccinia virus complement-control protein. J. Infect. Dis. 166:1245-50
335. Sahu A, SN Isaacs, AM Soulika, JD Lambris. 1998. Interaction of vaccinia virus complement control protein with human complement proteins: factor Imediated degradation of C3b to iC3b1 inactivates the alternative complement pathway. J. Immunol. 160:5596-604
336. Rosengard AM, JM Ahearn. 1998. Creation and functional characterization of SPICE, the smallpox inhibitor of complement enzymes. Mol. Immunol. 35:397
337. Kotwal GJ, CG Miller, DE Justus. 1998. The inflammation modulatory protein (IMP) of cowpox virus drastically diminishes the tissue damage by down-regulating cellular infiltration resulting from complement activation. Mol. Cell. Biochem. 185:39-46
338. Howard J, DE Justus, AV Totmenin, S Shchelkunov, GJ Kotwal. 1998. Molecular mimicry of the inflammation modulatory proteins (IMPs) of poxviruses: evasion of the inflammatory response to preserve viral habitat. J. Leukocyte Biol. 64:68-71
339. Miller CG, SN Shchelkunov, GJ Kotwal. 1997. The cowpox virus-encoded homolog of the vaccinia virus complement control protein is an inflammation modulatory protein. Virology 229:126-33
340. Kostavasili I, A Sahu, HM Friedman, RJ Eisenberg, GH Cohen, JD Lambris. 1997. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus. J. Immunol. 158:1763-71
341. McNearney TA, C Odell, VM Holers, PG Spear, JP Atkinson. 1987. Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity. J. Exp. Med. 166:1525-35
342. Friedman HM, L Wang, NO Fishman, JD Lambris, RJ Eisenberg, GH Cohen, J Lubinski. 1996. Immune evasion properties of herpes simplex virus type 1 glycoprotein gC. J. Virol. 70:4253-60
343. Huemer HP, Y Wang, P Garred, V Koistinen, S Oppermann. 1993. Herpes simplex virus glycoprotein C: molecular mimicry of complement regulatory proteins by a viral protein. Immunology 79:639-47
344. Lachmann PJ, A Davies. 1997. Complement and immunity to viruses. Immunol. Rev. 159:69-77
345. Hidaka Y, S Sakuma, Y Kumano, H Minagawa, R Mori. 1990. Characterization of glycoprotein C-negative mutants of herpes simplex virus type 1 isolated from a patient with keratitis. Arch. Viral. 113:195-207
346. Fodor WL, SA Rollins, S Bianco-Caron, RP Rother, ER Guilmette, WV Burton, JC Albrecht, B Fleckenstein, SP Squinto. 1995. The complement control protein homolog of herpesvirus saimiri regulates serum complement by inhibiting C3 convertase activity. J. Virol. 69:3889-92
347. Rother RP, SA Rollins, WL Fodor, JC Albrecht, E Setter, B Fleckenstein, SP Squinto. 1994. Inhibition of complement-mediated cytolysis by the terminal complement inhibitor of herpesvirus saimiri. J. Virol. 68:730-37
348. Vanderplasschen A, E Mathew, M Hollinshead, RB Sim, GL Smith. 1998. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc. Natl. Acad. Sci. USA 95:7544-49
349. Smith GL. 1999. Vaccinia virus immune evasion. Immunol. Lett. 65:55-62
350. Payne LG. 1980. Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J. Gen.-100
351. Saifuddin M, CJ Parker, ME Peeples, MK Gorny, S Zolla-Pazner, M Ghassemi, IA Rooney, JP Atkinson, GT Spear. 1995. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J. Exp. Med. 182:501-9
352. Spear GT, NS Lurain, CJ Parker, M Ghassemi, GH Payne, M Saifuddin. 1995. Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses: human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). J. lmmunol. 155:4376-81
353. Schmitz J, JP Zimmer, B Kluxen, S Aries, M Bogel, I Gigli, H Schmitz. 1995. Antibody-dependent complement-mediated cytotoxicity in sera from patients with HTV-I infection is controlled by CD55 and CD59. J. Clin. Invest. 96:1520-26
354. Marschang P, J Sodroski, R Wurzner, MP Dierich. 1995. Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur. J. lmmunol. 25:285-90
355. Spiller OB, BP Morgan, F Tufaro, DV Devine. 1996. Altered expression of host-encoded complement regulators on human cytomegalovirus-infected cells. Eur. J. lmmunol. 26:1532-38
356. Pascual M, C Danielsson, G Steiger, JA Schifferli. 1994. Proteolytic cleavage of CR1 on human erythrocytes in vivo: evidence for enhanced cleavage in AIDS. Eur. J. lmmunol. 24:702-8
357. Munson LG, ME Scott, AL Landay, GT Spear. 1995. Decreased levels of complement receptor 1 (CD35) on B lymphocytes in persons with HIV infection. Clin. lmmunol. Immunopathol. 75:20-25
358. Jouvin MH, W Rozenbaum, R Russo, MD Kazatchkine. 1987. Decreased expression of the C3b/C4b complement receptor (CR1) in AIDS and AIDS-related syndromes correlates with clinical subpopulations of patients with HIV infection. AIDS 1:89-94
359. Larcher C, TF Schulz, J Hofbauer, P Hengster, N Romani, H Wachter, MP Dierich. 1990. Expression of the C3d/ EBV receptor and of other cell membrane surface markers is altered upon HIV-1 infection of myeloid, T, and B cells. J. Acquired Immune Defic. Syndr. 3:103-8
360. Wahl SM, JB Allen, S Gartner, JM Orenstein, M Popovic, DE Chenoweth, LO Arthur, WL Farrar, LM Wahl. 1989. HIV-1 and its envelope glycoprotein down-regulate chemotactic ligand receptors and chemotactic function of peripheral blood monocytes. J. lmmunol. 142: 3553-59
361. Speth C, MP Dierich. 1999. Modulation of cell surface protein expression by infection with HIV-1. Leukemia 13(Suppl. 1):99-105
362. Pangburn MK, RD Schreiber, HJ Muller-Eberhard. 1981. Formation of the initial C3 convertase of the alternative complement pathway: acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J. Exp. Med. 154:856-67
363. Stoiber H, C Ebenbichler, R Schneider, J Janatova, MP Dierich. 1995. Interaction of several complement proteins with gp120 and gp41, the two envelope glycoproteins of HIV-1. AIDS 9:19-26
364. Pinter C, AG Siccardi, L Lopalco, R Longhi, A Clivio. 1995. HIV glycoprotein 41 and complement factor H interact with each other and share functional as well as antigenic homology. AIDS Res. Hum. Retrovir. 11:971-80
365. Stoiber H, C Pinter, AG Siccardi, A Clivio, MP Dierich. 1996. Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J. Exp. Med. 183:307-10
366. Horstmann RD, HJ Sievertsen, J Knobloch, VA Fischetti. 1988. Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc. Natl. Acad. Sci. USA 85:1657-61
367. Wiertz EJ, TR Jones, L Sun, M Bogyo, HJ Geuze, HL Ploegh. 1996. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 84:769-79
368. Wang GH, J Bertin, Y Wang, DA Martin, J Wang, KJ Tomaselli, RC Armstrong, JI Cohen. 1997. Bovine herpesvirus 4 BORFE2 protein inhibits Fas-and tumor necrosis factor receptor 1-induced apoptosis and contains death effector domains shared with other gamma-2 herpesviruses. J. Virol. 71:8928-32
369. Chacon MR, F Almazan, ML Nogal, E Vinuela, JF Rodriguez. 1995. The African swine fever virus IAP homolog is a late structural polypeptide. Virology 214:670-74
370. Revilla Y, A Cebrian, E Baixeras, C Martinez, E Vinuela, ML Salas. 1997. Inhibition of apoptosis by the African swine fever virus Bcl-2 homologue: role of the BH1 domain. Virology 228:400-4
371. Yew PR, AJ Berk. 1992. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature 357:82-85
372. Moore M, N Horikoshi, T Shenk. 1996. Oncogenic potential of the adenovirus E4orf6 protein. Proc. Natl. Acad. Sci. USA 93:11295-301
373. Mietz JA, T Unger, JM Huibregtse, PM Howley. 1992. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J. 11:5013-20
374. DeCaprio JA, JW Ludlow, J Figge, JY Shew, CM Huang, WH Lee, E Marsilio, E Paucha, DM Livingston. 1988. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 54:275-83
375. Liu JL, Y Ye, LF Lee, HJ Kung. 1998. Transforming potential of the herpesvirus oncoprotein MEQ: morphological transformation, serum-independent growth, and inhibition of apoptosis. J. Virol. 72:388-95
376. Upton C, JL Macen, M Schreiber, G McFadden. 1991. Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence. Virology 184:370-82
377. Spriggs MK, DE Hruby, CR Maliszewski, DJ Pickup, JE Sims, RM Buller, J VanSlyke. 1992. Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein. Cell 71:145-52
378. Alcami A, GL Smith. 1992. A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 71:153-67
379. Ray CA, RA Black, SR Kronheim, TA Greenstreet, PR Sleath, GS Salvesen, DJ Pickup. 1992. Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 beta converting enzyme. Cell 69:597-604
380. Smith GL, YS Chan. 1991. Two vaccinia virus proteins structurally related to the interleukin-1 receptor and the immunoglobulin superfamily. J. Gen. Virol. 72:511-18
381. Foster GR, AM Ackrill, RD Goldin, IM Kerr, HC Thomas, GR Stark. 1991. Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA. Proc. Natl. Acad. Sci. USA 88:2888-92. Erratum. 1995. Proc. Natl. Acad. Sci. USA 92(8):3632
382. Foster GR, RD Goldin, A Hay, MJ McGarvey, GR Stark, HC Thomas. 1993. Expression of the terminal protein of hepatitis B virus is associated with failure to respond to interferon therapy. Hepatology 17:757-62
383. Burysek L, WS Yeow, PM Pitha. 1999. Unique properties of a second human herpesvirus 8-encoded interferon regulatory factor (vIRF-2). J. Hum. Virol. 2:19-32
384. Kanda K, T Decker, P Aman, M Wahlstrom, A von Gabain, B Kallin. 1992. The EBNA2-related resistance towards alpha interferon (IFN-alpha) in Burkitt's lymphoma cells effects induction of IFN-induced genes but not the activation of transcription factor ISGF-3. Mol. Cell. Biol. 12:4930-36. Erratum. 1993. Mol. Cell. Biol. 13(3): 1981
385. Aman P, A von Gabain. 1990. An Epstein-Barr virus immortalization as sociated gene segment interferes specifically with the IFN-induced anti-proliferative response in human B-lymphoid cell lines. EMBO J. 9:147-52
386. Clarke PA, MB Mathews. 1995. Interactions between the double-stranded RNA binding motif and RNA: definition of the binding site for the interferon-induced protein kinase DAI (PKR) on adenovirus VA RNA. RNA 1:7-20
387. Park H, MV Davies, JO Langland, HWChang, YS Nam, J Tartaglia, E Paoletti, BL Jacobs, RJ Kaufman, S Venkatesan. 1994. TAR RNA-binding protein is an inhibitor of the interferon-induced protein kinase PKR. Proc. Natl. Acad. Sci. USA 91:4713-17
388. Benkirane M, C Neuveut, RF Chun, SM Smith, CE Samuel, A Gatignol, KT Jeang. 1997. Oncogenic potential of TAR RNA binding protein TRBP and its regulatory interaction with RNA-dependent protein kinase PKR. EMBO J. 16:611-24
389. Chang HW, JC Watson, BL Jacobs. 1992. The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase. Proc. Natl. Acad. Sci. USA 89:4825-29
390. Romano PR, F Zhang, SL Tan, MT Garcia-Barrio, MG Katze, TE Dever, AG Hinnebusch. 1998. Inhibition of double-stranded RNA-dependent protein kinase PKR by vaccinia virus E3: role of complex formation and the E3 N-terminal domain. Mol. Cell. Biol. 18:7304-16
391. McInnes CJ, AR Wood, AA Mercer. 1998. Orf virus encodes a homolog of the vaccinia virus interferon-resistance gene E3L. Virus Genes 17:107-15
392. Mossman K, P Nation, J Macen, M Garbutt, A Lucas, G McFadden. 1996. Myxoma virus M-T7, a secreted homolog of the interferon-gamma receptor, is a critical virulence factor for the development of myxomatosis in European rabbits. Virology 215:17-30
393. Karp CL, M Wysocka, LM Wahl, JMmAhearn, PJ Cuomo, B Sherry, G Trinchieri, DE Griffin. 1996. Mechanism of suppression of cell-mediated immunity by measles virus. Science 273:228-31. Erratum. 1997. Science 275:1053
394. Cao JX, PD Gershon, DN Black. 1995. Sequence analysis of HindIII Q2 fragment of capripoxvirus reveals a putative gene encoding a G-protein-coupled chemokine receptor homologue. Virology 209:207-12
395. Strockbine LD, JI Cohen, T Farrah, SD Lyman, F Wagener, RF DuBose, RJ Armitage, MK Spriggs. 1998. The Epstein-Barr virus BARF1 gene encodes a novel, soluble colony-stimulating factor-1 receptor. J. Virol. 72:4015-21
396. Chee MS, SC Satchwell, E Preddie, KM Weston, BG Barrell. 1990. Human cytomegalovirus encodes three G protein-coupled receptor homologues. Nature 344:774-77
397. Isegawa Y, Z Ping, K Nakano, N Sugimoto, K Yamanishi. 1998. Human herpesvirus 6 open reading frame U12 encodes a functional beta-chemokine receptor. J. Virol. 72:6104-12
398. Ahuja SK, PM Murphy. 1993. Molecular piracy of mammalian interleukin-8 receptor type B by herpesvirus saimiri. J. Biol. Chem. 268:20691-94
399. Graham KA, AS Lalani, JL Macen, TL Ness, M Barry, LY Liu, A Lucas, I Clark-Lewis, RW Moyer, G McFadden. 1997. The T1/35kDa family of poxvirus-secreted proteins bind chemokines and modulate leukocyte influx into virus-infected tissues. Virology 229:12-24
400. Lalani AS, J Masters, K Graham, L Liu, A Lucas, G McFadden. 1999. Role of the myxoma virus soluble CC-chemokine inhibitor glycoprotein, M-T1, during myxoma virus pathogenesis. Virology 256:233-45
401. Massung RF, V Jayarama, RW Moyer. 1993. DNA sequence analysis of conserved and unique regions of swinepox virus: identification of genetic elements supporting phenotypic observations including a novel G protein-coupled receptor homologue. Virology 197:511-28
402. Rode HJ, W Janssen, A Rosen-Wolff, JJ Bugert, P Thein, Y Becker, G Darai. 1993. The genome of equine herpesvirus type 2 harbors an interleukin 10 (IL10)-like gene. Virus Genes 7:111-16
403. Fleming SB, CA McCaughan, AE Andrews, AD Nash, AA Mercer. 1997. A homolog of interleukin-10 is encoded by the poxvirus orf virus. J. Virol. 71:4857-61
404. Yao Z, WC Fanslow, MF Seldin, AM Rousseau, SL Painter, MR Comeau, JI Cohen, MK Spriggs. 1995. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 3:811-21
405. Comeau MR, R Johnson, RF DuBose, M Petersen, P Gearing, T VandenBos, L Park, T Farrah, RM Buller, JI Cohen, LD Strockbine, C Rauch, MK Spriggs. 1998. A poxvirus-encoded semaphorin induces cytokine production from monocytes and binds to a novel cellular semaphorin receptor, VESPR. Immunity 8:473-82
406. Mold C, BM Bradt, GR Nemerow, NR Cooper. 1988. Epstein-Barr virus regulates activation and processing of the third component of complement. J. Exp. Med. 168:949-69
407. Albrecht JC, J Nicholas, KR Cameron, C Newman, B Fleckenstein, RW Honess. 1992. Herpesvirus saimiri has a gene specifying a homologue of the cellular membrane glycoprotein CD59. Virology 190:527-30
408. Kapadia SB, H Molina, V van Berkel, SH Speck, HW Virgin. 1999. Murine gammaherpesvirus 68 encodes a functional regulator of complement activation. J. Virol. 73:7658-70
409. Shchelkunov SN 1995. Functional organization of variola major and vaccinia virus genomes. Virus Genes 10:53-71
410. Isaacs SN, EJ Wolffe, LG Payne, B Moss. 1992. Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope. J. Virol. 66:7217-24
411. Engelstad M, GL Smith. 1993. The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence. Virology 194:627-37
412. MacCormac LP, JE Grundy. 1996. Human cytomegalovirus induces an Fc gamma receptor (Fc gammaR) in endothelial cells and fibroblasts that is distinct from the human cellular Fc gammaRs. J. Infect. Dis. 174:1151-61
413. Johnson DC, MC Frame, MW Ligas, AM Cross, ND Stow. 1988. Herpes simplex virus immunoglobulin G Fc receptor activity depends on a complex of two viral glycoproteins, gE and gI. J. Virol. 62:1347-54
414. Baucke RB, PG Spear. 1979. Membrane proteins specified by herpes simplex viruses. V. Identification of an Fc-binding glycoprotein. J. Virol. 32:779-89
415. Para MF, L Goldstein, PG Spear. 1982. Similarities and differences in the Fc-binding glycoprotein (gE) of herpes simplex virus types 1 and 2 and tentative mapping of the viral gene for this glycoprotein. J. Virol. 41:137-44
416. Thale R, P Lucin, K Schneider, M Eggers, UH Koszinowski. 1994. Identification and expression of a murine cytomegalovirus early gene coding for an Fc receptor. J. Virol. 68:7757-65
417. Oleszak EL, J Kuzmak, B Hogue, R Parr, EW Collisson, LS Rodkey, JL Leibowitz.. 1995. Molecular mimicry between Fc receptor and S peplomer protein of mouse hepatitis virus, bovine corona virus, and transmissible gastroenteritis virus. Hybridoma 14:1-8
418. Litwin V, W Jackson, C Grose. 1992. Receptor properties of two varicella-zoster virus glycoproteins, gpI and gpIV, homologous to herpes simplex virus gE and gI. J. Virol. 66:3643-51